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Whooping cough is an ubiquitous respiratory infection that primarily affects young
children . A cellular vaccine, composed ofinactivated Bordetellapertussis cells, was in-
troduced in the 1940s and has been successfully used for many years in prevention
ofwhooping cough (1). However, in recent years the side effects associated with the
cellular vaccine (2, 3) have decreased its use in several countries, with the result of
a sharp increase in infant mortality caused by the disease- (1, 4) . A more defined
vaccine, composed of protective B . pertussis antigens, could be safer and more reli-
able to reintroduce mass vaccination . There are several candidate antigens for this
approach : pertussis toxin (PT)t, filamentous haemagglutinin, 69-kD outer mem-
brane protein, and pili (5, 6) . Indeed, a cell-mediated immunity against most of
these antigens has been shown in human donors immunized by the disease (7) . In
particular, PT has been shown to be highly protective in animal models (8) and a
recent field trial held in Sweden has confirmed that PT has a protective role also
in humans (9) .
PT is an oligomeric protein organized in five subunits that can be divided into
twofunctionally different moieties : part A, composed ofsubunit Sl, andpart B, com-
posed of subunits S2, S3, S4, and S5 (10) . In analogy with exotoxinA from Pseudo-
monas aeruginosaanddiphtheriaandcholera toxins, theA moiety hasADPribosyltrans-
ferase activity, while theBmoiety binds thereceptor(s) onto the surface of eukaryotic
cells and allows the entry ofthe catalytic subunit Sl into the cell . The several biolog-
ical effects exerted by PT (8) are mediated by the enzymatic activity of subunit Sl,
which has as target a family ofGTP-binding proteins involved in the transduction
of signals across the cell membrane of eukaryotic cells (11, 12) .
Although the genes encoding the five subunits ofPT have been cloned and se-
quenced (13, 14), all attempts to express the complete PT in prokaryotic vectors have
so far failed (15) . Oneway to overcome these problems and to obtain a vaccine that
can be produced on a large scale may be to develop immunogenic recombinant or
synthetic derivatives of PT . Subunit S1 may be the best candidate for this purpose .
In fact, mAbs against Sl have been shownto neutralize the toxin in vitro andprotect
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mice againsttheintracerebral challenge with virulent B. pertussis (16) . Furthermore,
by raising polyclonal and monoclonal antibodies against the holotoxin, it was found
that Sl is the most immunogenic among PT subunits (16, 17, Rappuoli et al., un-
published data). However, since recombinant Sl by itself has been shown unable
to induce protective antibodies in mice becauseof conformational problems (15, 18),
it is worthy of investigation to assess whether oligopeptides from Sl subunit may
function in inducing protection towards the infection, circumventing the structural
problems. Therefore, the rational development of a peptide-based vaccine requires
the identification of B and T cell epitopes.
As an extension of our previous studies on B cell epitopes of the subunit Sl (18),
in this study we have raised human T cell clones against PT and S1 from the blood
of a donor immune to pertussis and have analyzed their fine specificity. PTspecific
clones were tested for recognition of the five recombinant subunits of PT, and Sl-
specific clones were used to map T cell epitopes on SI by using recombinant frag-
mentsand syntheticpeptides homologous to this protein, as well as mutated Sl subunits
deriving from two bacterial species related to B. pertussis.
Materials and Methods
Antigens.
￿
PT was purified from B. pertussis phase I culture supernatant as described by
Sekura et al. (19), precipitated in ammonium sulfate, and kept at 4°C. Before use, PT was
resuspended in PBS and heat inactivated (at 100°C for 45 min) to eliminate its mitogenic
effect (20).
Subunits Sl, S2, S3, S4, S5 from B. pertussis, BPPSI, BBSI, and nine fragments of BPSI
were expressed in Escherichia coli. Each protein was fused to the NH2-terminal 98 amino acids
of the MS2 polymerase (15, 21, 22). Recombinant plasmids expressing NH2-terminal and
COOH-terminal deletions of the Sl were obtained by standard DNA manipulation tech-
niques as described (22). All the fusion proteins were partially purified by lysing the bacteria
and collecting the inclusion bodies (15). The total protein concentration obtained was gener-
ally between 0 .5 and 1 mg/ml with the 10-50°Jo represented by the fusion protein (see Fig.
1 for BPSI and its fragments). Inclusion bodies were resuspended in PBS and stored at -20°C.
Recombinant proteins were used in proliferation assays without any further purification, at
a final concentration of til Wg/ml of the fusion protein. Subunit Sl was further purified by
electroelution as described (15) to stimulate the generation ofspecific T cell clones from PBMC.
Synthetic peptides of subunit St were obtained from different sources. Peptide 2-15 was
purchased from Novabiochem (Laufelfingen, Switzerland). Peptides 6-17 and 27-39 were
kindly donated by D. Burns (Center for Drugs and Biologics, FDA, Bethesda, MD). Peptides
8-18, 171-194, and 171-185 were prepared at the Sclavo Research Center by R. Presentini.
Peptide 212-227 was purchased from G. Corradin (Universite de Lausanne, Epalinges, Swit-
zerland) .
Mediafor Cell Stimulation and Growth.
￿
The culture medium was RPMI 1640 (Gibco Labora-
tories, Paisley, Scotland) supplemented with L-glutamine (2 mM), l7o nonessential amino
acids, 1% sodium pyruvate, 50 jig/ml gentamycin, 5 x 10-5 M 2-ME and 10°70 heat-
inactivated pooled human AB serum (RPMI-HS) or FCS (RPMI-FCS). To support the
antigen-independent growth of T cell clones, RPMI-HS was supplemented with 50 U/ml
human rIL-2 (Hoffmann-La Roche, Inc., Nutley, NJ).
Cloning ofAntigen-speck TLymphocytes.
￿
T cell clones were obtained from peripheral blood
ofdonor R.R., previously used to identify antigens from Bordetella species (7) . His HLA class
II phenotype was defined as DR 1, 2, DR w16, DQ wl, DQ w5. PBMC isolated from
heparinized blood of donor R.R. by Ficoll-Hypaque (Pharmacia Fine Chemicals, Uppsala,
Sweden) were cultured in 96-well flat-bottomed plates (Costar, Cambridge, MA) at the con-
centration of 2 x 105/well in 0 .2 ml RPMI-HS, in the presence of heat-inactivated PT or
St at different concentrations (threefold dilutions from 10 to 0 .1 jug/ml, in the final volume).DE MAGISTRIS ET AL.
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After assessment of antigen-induced proliferation by [3H]thymidine incorporation, rIL-2 was
added on day 7 to expand the proliferating cells. After another 7 d, lymphoblasts from several
wells were pooled and cloned by limiting dilution. Cells were seeded at 0.3 per well in Ter-
asaki traysin the presence of 104 allogeneic mitomycin C-treated PBMC, in RPMI-HS con-
taining PHA (1 Ag/ml), and rIL-2 (23). These clones were maintained in culture by periodic
restimulation in the presence of allogeneic mitomycin C-treated PBMC, PHA, and rIL-2.
Clones ofT lymphocytes were analyzed for cell surface phenotype by direct immunofluores-
cence on a FAGS (FACStar, Becton Dickinson & Co., Erembodegem, Belgium). Both
phycoerythrin- and fluorescein-conjugated OKT3, OKT4, and OKT8 mAbs (Ortho Diag-
nostic Systems, Inc., Raritan, NJ) were used.
Immortalization ofBLymphocytes with EBV.
￿
PBMC from donor R.R. were transformed with
EBV as described (24). Briefly, 101 PBMC were resuspended in 10 ml RPMI-FCS containing
30% supernatant ofthe EBVproducing marmoset cell line B95.8 and 600 ng/ml cyclosporin
A (Sandoz, Basel, Switzerland) and were distributed in a flat-bottomed 96-well plate at 5 x
104/well.
Proliferation Assays.
￿
Clones of T lymphocytes were incubated at 2 x 104 cells/well for 3 d
in the presence of 2 x 104 mitomycin C-treated or 104 irradiated EBVtransformed autolo-
gous B lymphocytes (EBVB cells) and antigens in RPMI-FCS, in 96-well flat-bottomed plates.
In the experiment determining DR restriction, two allogeneic DR homozygous EBVB cell
lines (kindly provided by E. Goulmy, Leiden, The Netherlands) were used: EDR (DR 1)
and NOL (DR 2). Cells were first pulsed for 2 h with 10 Ag/ml of peptide, then thoroughly
washed and irradiated before being used in the proliferation assays. All assay cultures were
pulsed for the last 16-18 h with 1 ACi of [3H]thymidine (sp. act. 185 GBq/mmole; Amer-
sham International, Amersham, UK). Cells were then harvested on glass fiber filters with
a cell harvester (Skatron, Inc., Lier, Norway) and incorporated radioactivity was determined
by liquid scintillation counting. Results ofproliferation assays are presented as the mean cpm
of triplicate cultures t SD. Statistical significance was analyzed by student's t test for stimu-
lation indices (SI) <3, where SI = cpm of cultures with antigen/cpm of cultures without an-
tigen. A large number of experiments indicated that SI>3 is always statistically significant.
Positive values in the tables are boxed.
Inhibition Assay with mAbAnti-HLA Class 11Molecules.
￿
2 x 104 cells from each clone were
cultured with 104 autologous irradiated EBVB cells. Appropriate dilutions of the peptides
27-39 or 171-194 were added simultaneously with 8 1Ag/ml final dilution of mAb anti-DR
(L243), anti-DP (B7 .21), or anti-DQ(Leu-10) (Becton Dickinson & Co., Miichenstein, Swit-
zerland), in a final volume of 250 pl. After 48 h cultures were pulsed with [3H]thymidine
and harvested as described in the previous section.
Results
Fine Spec city ofHuman T Cell Clones Against PT.
￿
In a previous study (5), an adult
donor (R.R.) was identified as being immune against B. pertussis. In fact, he had
suffered from pertussis in his childhood and exhibited significant humoral and cel-
lular responses against B. pertussis antigens. Thus, T cell clones against PT were ob-
tained from his PBMC (5). Here, the fine specificity of T cell clones against PT
was further analyzed using recombinant PT subunits (13). 10 of 12 clones (83%)
were specific for Sl (Table I), suggesting that this subunit might be immunodominant
in this individual. Of the other two clones, T106 is directed to S4 and T207 recog-
nizes a crossreactive determinant on subunits S2 and S3, which share 67% amino
acid homology. None of the clones proliferated to S5. To have a suitable number
of clones neccesary for mapping the Sl epitopes, PBMC were stimulated in vitro
with recombinant Sl, obtaining eight additional specific clones (Table 1). All the
clones used have phenotype CD3+4+8-.
Mapping T Cell Epitopes on S1.
￿
To identify the regions of Sl containing the epi-
topes recognized by the Sl-specific T cell clones, recombinant proteins representingz
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NH2- and COOH-terminal deletions of S1 (Fig . 1, Fig. 2, and reference 18) were
assayed for their ability to stimulate T cell clones . Differential recognition of the
recombinant fragments by 10 representative clones of the 18 tested is reported in
Table II . In addition to the truncated fragments, therecombinant full-length S1 from
both Bordetella parapertussis (BPPSI) and Bordetella bronchiseptica (BBSI), were used as
antigen in proliferation assays . These two proteins differ fromBPS1 forsome amino
acid substitutions along their sequence (10 substitutions in BPPSI and four in BBSI)
(Fig . 3 and reference 21). 11 of 18 clones tested map at theNH2 terminus of S1 (Fig .
2) . In fact, they recognize the NCO, NRU, BAL, and SPH fragments, but none
of the fragments with deletions of the NH2-terminal portion of the protein. The
shorter deletion at the NH2 terminus that abolishes clone proliferation is that of
fragment 34a, which is 42 residues long . The sequence 1-42 is therefore likely to
contain the epitope(s) recognized by these clones, although NH2-terminal residues
of fragment 34a may also be involved . The unresponsiveness to BPPS1 and BBSI
of 5 of these 11 clones (S229, S232, T215, T219, and T226) suggests that at least
two different specificities are represented in this group . The mutation Asp- Glu34,
present in both BPPS1 and BBSI (Fig. 3), is therefore crucial for recognition of the
protein .
On the basis of their pattern of recognition of the recombinant fragments (Table
II and Fig . 2), the remaining seven clones were found to map at the COOH ter-
minus of S1, since they recognized all the fragments truncated at the NH2-terminal
end, including fragment 18, which contains only amino acids 150-235 (Fig . 2) . Of
the fragments deleted inCOOH terminus, five clones (S105, S201, T209, T217, and
T227)recognized only NCO and34a . This allows the exclusion ofthe last 24 residues
of Sl as the sequence containing the epitopes recognized by these clones . Such epi-
topes mayinsteadbe comprisedbetweentheCOOH end ofNRUandthe lastCOOH-
terminal residue ofNCO, in region 181-211, although someCOOH-terminal residues
ofNRUmay also be part of an incomplete epitope . Finally, clones S223 and T216
map at the veryCOOH-terminal end of Sl . In fact, both recognize all the fragments
FIGURE 1 .
￿
Comassie blue-stained SDS-PAGE of
theE . coli inclusion bodies containingthe recom-
binant BPSI subunit and its fragments (arrows)
used in the proliferation assays.1524
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FIGURE 2 .
￿
Mapping ofT cell epitopic regions of Sl with recombinant fragments and mutated
Sl from B. parapertussis and B. bronchiseptica (BPPSI and BBSI) . The thick black line indicates
B. pertussis Sl . Above are reported the restriction enzymes used to obtain the recombinant frag-
ments (22) . Lettersbelow the black line indicate the twoamino acid substitutions of BPPSI and
BBSI that caused unresponsiveness to these two proteins by the clones listed in the lower part
of the figure and designed with BPP- and BB- . The thin lines represent BPS1 recombinant frag-
ments with COOH-terminal and NH2-terminal truncations ; their names are indicated on the
left . Specificity of the clones was the following: clones 5106, S208, S213, T218, T220, and T229
recognized BPPSI, BBSI,and truncated fragments indicated with O+ on the left part ofthe figure.
Clones 5229, S232, T215, T219, andT226 recognized the same truncated fragments oftheupper
reported clones, however, themutation D-E impaired recognition ofBPPSI and BBSI . Shaded
1-42 segment represents the region of BPSl deduced to contain T cell epitopes for these eleven
clones . Clones Sí05, S201, T209, T217, and T227 recognized BPPSI, BBSI, and truncated pep-
tides indicated with © in the middle-right part ofthe figure . Shaded 181-211 segment represents
the region deduced to contain T cell epitopes for these five clones . Clones S223 and T216 both
recognized BBSI and truncated fragments indicated with p on the right-end part of the figure,
however mutationA-Tof BPPSI impaired recognition of BPPSI by clone5223 . Shaded 212-235
segment represents the region deduced to contain T cell epitopes for these last two clones.
truncated at the NH2 terminus and do not recognize the fragments truncated at
the COOH terminus . This indicates that the deletion 212-235 at the COOH end
ofNCO and 34a is enough to abolish recognition of Sl and is therefore likely to
contain the epitopes recognized by thesetwo clones . The specificity ofthe twoclones
is different, since S223 does not recognize BPPSI. The mutation Ala- Thr2t9 , pe-
culiar to BPPSI, is very likely the cause of this unresponsiveness .
Recognition of Synthetic Peptides.
￿
In the attempt to identify the minimal sequence
capable of stimulatingT cells in the regions 1-42, 181-211, and 212-235, synthetic
peptides homologous to NH2-terminal and COOH-terminal portions of BPS1 (Fig .
3) were used as stimulators in proliferation assays in the presence ofEBVB cells .
Clones mapping in the NH2-terminal region 1-42 were stimulated with the over-
lapping peptides 2-15, 6-17, 8-18, and with the peptide 27-39, which is homologous
to the sequence that in BPPSI and BBSI contains the mutation Asp -" Glu34 . As
shown in Table III, threeof the five clones tested (which were able to recognize BPSl,1
BPS1
BPPSI
BBS1
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FIGURE 3 .
￿
Amino acid sequence ofBPS1 according to Nicosia et al . (13) andamino acid muta-
tions in BPPSI andBBSI sequences . The synthetic peptides homologous to BPSI, used to stimu-
lateT cell clones, are also shown . Boxed areas represent the regions 1-42, 181-211, and212-235
that contain T cell epitopes .
but not BBSI or BPPS1) specifically proliferated to peptide 27-39 . Therefore, the
epitope recognized by clones S232, T215, and T226 is contained within a sequence
of 13aa . On the other hand, clone S229 and T219 did not respond either to 27-39
or to any other peptide . In this regard, these clones introduce a different specificity
in the group of clones mapping at the NH2 terminus . The other six clones map-
ping in the region 1-42, all responsive to both BPPSI and BBS1, did not recognize
any of the peptides listed in Table III (data not shown) .
The five clones mapping in the COOH-terminal region 181-211 were tested for
recognition of the peptides 171-185 and 171-194, which are homologous in the first
15 amino acids . Table III shows that four of the five clones proliferated to peptide
171-194, butnot 171-185 . This indicates that clones S105, S201, T209, and T217map
in a region of 24 residues (171-194), but suggests that the epitope recognized is shifted
on the second half of the sequence 171-194 . Clone T227, which did not recognize
either ofthe previous twopeptides, introduces a different fine specificity in thegroup
of clones mapping in the region 181-211 .
Clones S223 and T216, mapping in the sequence 212-235, were not stimulated
by the peptide 212-227, which includes the Ala219, which, when substituted with
Thr, abolishes the response of 5223 to BPPS1 .
Determination ofHLA Class II Restriction.
￿
An inhibition assay with mAbs against
HLA class II molecules DR, DP, andDQwas performed to determine the restric-
tion element used by the clones recognizing the stimulatory peptides 27-39 and
171-194 . Clone T215 (specific for 27-39) and clones S105 and T217 (both specific
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Boxed values are statistically significant (p 4 0.05).
* Clones mapping at the NHz terminus.
t Mean cpm (x 10- ;) ± SD of triplicate cultures.
Clones mapping at the COON terminus.
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TABLE III
Proliferation of T Cell Clones Induced by Synthetic Peptides Homologous to S1
for 171-194) were cultured with autologous EBVB cells, threefold dilutions of the
appropriate peptide, and mAbs. Onlyanti-DRantibodies showed an inhibitoryeffect
on antigen-induced proliferation. In fact, the response ofclones T215 and 5105 was
strongly inhibited by these antibodies and the response ofclone T217 was evenabol-
ished (Fig. 4). Therefore, these three clones recognize the respective peptides in the
context ofDR molecules. In a second experiment, designed to determine the DR
allele involved, two allogeneic lymphoblastoid cell lines, EDR homozygous forDRl
and NOL homozygous for DR2, were used to present the peptides to clones S232,
T215, T226, and T217. Thecell lines were first pulsed with one or the otherpeptide
to allow binding ofthe peptides to class II molecules, then irradiated and cultured
with the clones. Table IV shows that only the line EDR (DR1) was capable ofpre-
senting the antigen to the clones as the autologous EBVRR. This indicates that
DRl is the restriction element used by the clones tested.
FIGURE 4.
￿
Inhibition ofpeptide recognition
by anti-class II mAbs (N, anti-DR; *, anti-
DP; A, anti-DQ). This experiment wasper-
formed with autologous irradiated EBVB
cells. cpm, of controls without antigen of the
three clones were, respectively, 1.6, 1.9, and
1.8 x 103. Anti-DP and anti-DQantibodies
were not inhibitory vs. control (not shown).
RR-T219
RR-T226
1 .4±0.2
0.9 ± 0.2
1 .1 ±0.1
ND
1 .3 t0.8 2 .0 t 0.9
0.7 ± 0.1 ND
Peptides (hg/ml)
2.4 ± 2.6
44.3 t 4.2
Clone' None 171-194 (1) 171-185 (10) 212-227 (10)
RR-S105 1 .7 t 0.21 96.5 t 12.3 1.4 t 0.1 ND
RR-S201 2 .6 ± 0.3 20.4 f 2 .6 2 .2 t 0.1 ND
RR-T209 1 .5 ± 0 .2 72.5 t 7 .8 1 .0 t 0.1 ND
RR-T217 3.5 ± 0.9 47.5 t 5 .0 2.6 t 0.1 ND
RR-T227 2.5 ± 0 .3 2.2 t 0.1 2.4 t 0.1 ND
RR-T216 0.5 ± 0.1 ND ND 0.6 ± 0.1
RR-5223 0.6 ± 0.1 ND ND 0.7 t 0.1
Peptides (Ag/ml)
Clone* None 2-15 (10) 6-17 (10) 8-18 (10) 27-39 (10)
RR-S229 1 .6 t 0.31 1 .4 ± 0 .2 1 .0 t 0.2 1 .6 t 0.1 0.7 t 0.1
RR-S232 0.8 ± 0.2 ND 0.9 t 0.1 ND 9 .2 t 1 .1
RR-T215 1 .8 ± 0.4 1 .5 t 0.1 1-3 t 0.1 2.3 ± 0.4 45.9 t 10.41528
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TABLE IV
Recognition of Peptides Presented by an Allogeneic DR 1,1 EBV-B Cell Line
Boxed values are statistically significant (p < 0.05) .
Ocpm (x 10-3) ± SD ofduplicate cultures (background proliferation values ranged between
6.2 and 8.4 cpm x 103).
Discussion
We have shown that the S1 subunit of PT is recognized by most (10 of 12) of the
human T cell clones against PT. This result suggests immunodominance of the Sl
over the otherfour subunits of PT in humans. The immunodominance of this enzy-
matically active subunit, previously shown in mice (16, 17), goats, rabbits(Rappuoli
et al., unpublished data), and here, in humans, renders this toxin quiteunique among
the otherbacterial toxins with A-B structure, as diphtheria and choleratoxins where
the B oligomer hasbeen demonstrated to be farmore immunogenicthan A (25-27).
Based on this, subunit S1 seems to be a good candidate for a recombinant or syn-
thetic vaccine against whooping cough. However, since recombinant Sl failed to
induce protection, probably due to adifferent foldingcaused by the expression systems
(15, 18), it remains to identify the short peptides of Sl recognized by humoral and
cellular immunity. A majorprotective B cell epitopeof the subunitSl, which is com-
posed of at least two noncontiguous regions mapping at the NH2 terminal and
COOH terminal of the protein, was previously reported by our group (18). The
identification of some T cell epitopes of the subunit Sl was here performed using
the 10 above-mentioned S1-specific Tcell clones plus eight newly generated against
S1 itself, all with the helper/inducer phenotype CD3+CD4+CD8-. Clones were first
tested for recognition of nine recombinant fragments of S1, representing deletions
of different lengths at the NH2-terminal and/or COOH-terminal regions of the pro-
tein. Three regions containing antigenic sites were identified: fragment 1-42 (recog-
nized by 11 clones) at the NH2 terminus and fragments 181-211 and 212-235 (rec-
ognized by five and two clones, respectively), which are adjacent and situated at
the COOH terminus of Sl. It is noticeable that anti-Sl clones raised either against
the purified PT or the recombinant Sl showed similar patterns of specificity. This
would indicate that the fusion of S1 to the polymerase of phage MS2 does not alter
antigen processing ofthe protein. Clones were also tested for recognition of two mu-
tated S1 proteins deriving from two B. pertussis-related species, i.e., B. parapertussis
and B . bronchiseptica. Although these species contain transcriptionally silent PT genes
(21), the respective Sl proteins can be expressed in E. coli (21). The recombinant
proteins obtained are enzymatically active and differ from BPSI only for few amino
acid substitutions along their sequence (21). Two mutations (Asp -" Glu34 and Ala-
Thr2'9) completely abolished proliferation of some clones, indicating that those resi-
dues might be part of an epitope.
Clone Peptide EBV-RR (DR 1,2)
APC
EDR (DR 1,1) NOL (DR 2,2)
RR-S232 27-39 64.5' t 16 .3 151 .4 ± 20.1 0.3 t 0.4
RR-T215 27-39 206.4 t 17 .9 176.5 t 45.8 1 .0 t 0.2
RR-T226 27-39 166.3 ± 6 .3 200.7 t 47.0 0.0 t 0.6
RR-T217 171-194 82.2 t 5.3 44.8 t 8.0 1 .4 ± 0.4DE MAGISTRIS ET AL.
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Synthetic peptides were then assayed for their capability to stimulate the clones.
Peptide 27-39was recognized by three ofthe five clones affected in the antigenrecog-
nition by the substitution Asp -Glu". This suggests that an immunodominant site
is located around residue 34 and that a polyclonal T cell response is directed to this
antigenic site. It is not clear, however, whetherthe other six clones mapping inregion
1-42, but which are not affected by the substitution Asp -" G1u34, are also directed
to this immunodominant region or rather recognize a distinct NH2-terminal se-
quence. At the other end of the protein, peptide 171-194 was recognized by four of
the five clones mapping in the sequence 181-211, and there is evidence that the anti-
genic site may be localized in the COOH-terminal half ofthe sequence 171-194.
The primary sequence of the operationally defined T cell epitopes was analyzed
a posteriori with the two most common methods for predicting immunogenic sites
(28, 29). In peptide 27-39 residues AsnVal-Leu-Asp (31-34) correspond to a con-
sensus motif (charged or glycine-hydrophobic-hydrophobic-polar or charged), sug-
gested by Rothbard (28) as being common to a majority of T cell determinants.
Moreover, the optimized algorithm for predicting Tcell antigenic sites (developed
by Margalit et al.) (29) was applied to S1 sequence. Residues 26-42 can form an am-
phipatic helix and can be accommodated in a helical wheel such that residue 34 is
on the hydrophilic side, as might be anticipated ifAsp34 was associated with TCR
interaction. Peptide 171-194 contains part ofthe sequence 181-198, which has a high
amphipatic score (29). This supports the hypothesis that a T cell epitope is localized
in the second half of the sequence 171-194. There are no consensus sequences ac-
cording to Rothbard et al. (28) in peptide 171-194.
In a very recent study, Oksenberg et al. (30) reported the mapping ofT cell epi-
topes ofS1 obtainedwith the approach opposite toours, that isprediction ofimmuno-
genic peptides followed by in vitro confirmation experiments. It was therefore ofin-
terest to compare effectiveness ofthe two approaches. Whileboth studiesfinda major
epitope in the NH2-terminal region, Oksenberg et al. (30) described also antigenic
peptides homologous to the central region of S1, where none ofour clones map. It
could be that some ofthose peptides are not generated during the natural processing
of the S1 subunit. Furthermore, the COOH-terminal region of S1 was recognized
by our clones, but it was not included in the other study (30). Thus, it can be con-
cluded thatcomputerprediction can be useful, but not satisfactory iftaken on its own.
The development ofapeptide-based vaccine requires either a universal T cell epi-
tope, which is recognized by all the HLA types, or a mix"ure ofpeptides containing
enough epitopes to cover the majority ofthe population (31). The peptides described
here are DR1-restricted, and while further studies will establish whether they are
also recognized in the context ofother HLA types, it is important to include them
in a vaccine made by a pool of peptides. Thus, taking together this observation,
our previous findings about the B cell epitopes of S1, and the two peptides, 64-75
and 151-161, described by Oksenberget al. (30), which are immunogenic in a panel
ofindividuals with different HLA genotypes, a peptide-based vaccine seems ready
to be tested for its capability ofinducingprotection from the infection inexperimental
systems. Meanwhile, thepossibility ofobtaininganimproved acellularpertussis vaccine
containing engineered PTlacking ofthe S1 enzymatic activity is beinginvestigated
(32-34). Thesemutated molecules should be engineered in a way that theywill still
contain the protective epitopes. Our study shows that some of the mutations de-1530
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scribed, which abolish the enzymatic activity of Sl (22, 32), fall in a region that
does not contain T cell epitopes. Therefore, such vaccines are theoretically feasible.
Summary
Human T lymphocyte clones specific for pertussis toxin (PT) were used to ana-
lyze the fine specificity of the response to PT, the basic component of new acellular
vaccines against whooping cough. The majority (83%) of the clones specific for PT
recognized Sl, the subunit that in animal models has been shown to be highly im-
munogenic. To map T cell epitopes on Sl, 18 S1-specific clones were tested for recog-
nition of recombinant fragments representing NH2-terminal and COOH-terminal
deletions of Sl and two recombinant Sl subunits containing amino acid substitu-
tions. This approach led to the identification of three regions of the protein as the
sequences containing T cell antigenic sites: 1-42, 181-211, and 212-235. Synthetic
peptides were eventually used for a finer localization of the T cell epitopes. Two pep-
tides, one of 13 residues (27-39) at the NH2 terminus and one of 24 residues
(171-194) at the COOH terminus, stimulated proliferation ofthree and four clones,
respectively. Both peptides are recognized in association with HLA DRi molecules.
These results stress the role of Sl in the immune response to PT and provide data
useful for the development of a recombinant or synthetic antipertussis vaccine con-
taining T cell epitopes from Sl.
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